NCT06012734View on ClinicalTrials.gov

LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients

PHASE1RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

June 18, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Metastatic Microsatellite-stable Colorectal Cancer
Interventions
DRUG

LB-100

IV on day 1 and day 3

DRUG

Atezolizumab

IV on day 1

Trial Locations (1)

1066CX

RECRUITING

Antoni van Leeuwenhoek, Amsterdam

All Listed Sponsors
lead

The Netherlands Cancer Institute

OTHER